Invanz (ertapenem) / Merck (MSD) - LARVOL DELTA

Intravenous Fosfomycin in hospitalized patients with complicated urinary tract infections due to Third-generation cephalosporinresistant Enterobacterales (clinicaltrialsregister.eu) - P4 | N=548 | Recruiting | Sponsor: Azienda Ospedaliero Universitaria Di Modena | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Nephrology

CLINICAL FEATURES AND TREATMENT OF RENAL ABSCESS IN CHILDREN (ISN-WCN 2026) - "Initial treatment involved intravenous infusion of broad-spectrum antibiotics (piperacillin-tazobactam, meropenem, or ertapenem) for anti-infection therapy...Follow-up within 2 weeks after discharge showed complete resolution of renal abscesses without renal scar formation. No recurrence was observed during the outpatient follow-up period after discontinuation of medication.Conclusion The use of broad-spectrum antibiotics for the treatment of pediatric renal abscesses has proven to be effective and can be recommended as the first-line therapeutic approach."

Clinical • Infectious Disease • CRP

RENAL ABSCESS COMPLICATED BY ACUTE KIDNEY INJURY IN A 33-YEAR-OLD YOUNG, HEALTHY, NON-DIABETIC ADULT WITHOUT STRUCTURAL URINARY TRACT ABNORMALITIES: A CASE REPORT (ISN-WCN 2026) - "Intravenous Piperacillin-Tazobactam was initiated, and the patient underwent ultrasound-guided nephrostomy tube insertion with an intra-operative finding of purulent discharge extracted from the right kidney...The antibiotic regimen was shifted to Ertapenem based on culture susceptibility results...Early imaging, percutaneous drainage, prolonged intravenous antibiotic therapy, and supportive renal management are vital components of care. Clinicians should maintain a high index of suspicion for renal abscess in patients with persistent flank pain and fever unresponsive to antibiotic therapy for early detection and timely intervention, thereby preserving both renal function and improving overall outcomes."

Case report • Clinical • Acute Kidney Injury • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease

Temocillin: a therapeutic alternative in bone and joint infections due to third generation cephalosporin-resistant Enterobacterales? (PubMed, J Antimicrob Chemother) - "This study demonstrated the high in vitro efficacy of temocillin against 3GC-R Enterobacterales from BJIs, regardless of the underlying resistance mechanism. However, dosage adjustments based on the strain's MIC and the patient's renal function are crucial for optimal efficacy."

Journal • Infectious Disease

Value-Based Healthcare analysis of antibiotic administration in non-hospital settings: assessment of patient benefits and economic sustainability of the system. (PubMed, Recenti Prog Med) - "The OPAT v2.0 model demonstrates clinical and economic effectiveness, reducing hospital costs and improving quality of care. However, full implementation requires better territorial organisation, with home administration only for non-self-sufficient patients, while self-sufficient patients should be administered at district clinics in order to relieve congestion in hospital clinics."

Clinical • Journal • Infectious Disease

Ertapenem vs meropenem for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales: an ASTARTÉ post hoc analysis (ESCMID Global 2026) - No abstract available

Late-breaking abstract • Retrospective data

Comparison of in vitro antimicrobial activity of tebipenem, sulopenem, meropenem, and ertapenem against cefotaxime-resistant Enterobacterales (ESCMID Global 2026) - No abstract available

Preclinical

In vitro activity of once-daily, investigational antibiotic, ertapenem/zidebactam (WCK 6777) against carbapenemase-producing E. coli and K. pneumoniae collected from Indian tertiary care hospitals (ESCMID Global 2026) - No abstract available

Preclinical • Infectious Disease • Pneumonia

Assessing the impact of adjunctive ertapenem on persistent MSSA bacteraemia safety and efficacy outcomes (ESCMID Global 2026) - No abstract available

Clinical • Cardiovascular • Infectious Disease • Septic Shock

CRISPR-Cas9-mediated elimination of plasmid-borne carbapenemase genes restores ertapenem susceptibility in clinical Klebsiella pneumoniae isolates. (PubMed, Biomed J) - "This study demonstrates that CRISPR/Cas9-based genome editing can eliminate plasmid-encoded carbapenemase genes in clinical CRKP isolates and, in specific genetic contexts, facilitate the concurrent removal of associated quinolone resistance determinants. These findings support CRISPR-based genome editing as a proof-of-concept strategy for addressing plasmid-mediated multidrug resistance in Gram-negative pathogens."

Journal • Gene Therapies • Infectious Disease • Pneumonia

Assessing Solid Organ Transplant-Readiness in Patients with Hidradenitis Suppurativa (AAD 2026) - "A final patient, stabilized with prolonged intravenous ertapenem, also experienced delays due to transplant team uncertainty... Our cohort comprised five HS patients evaluated for SOT: four kidney transplants (including two kidney-pancreas) and one cardiac transplant. Ages ranged 29–43 years; three were male; four African American, one Hispanic. Mean HS-PGA at time of study enrollment was 1.4 (0–5 scale); mean NRS-pain was 1.4 (0–10 scale)."

Clinical • Dermatology • Hidradenitis Suppurativa • Immunology • Infectious Disease • Inflammation • Solid Organ Transplantation • Transplantation

Efficacy and Durability of Extended (>16 Weeks) Intravenous Ertapenem for Treatment of Hidradenitis Suppurativa (AAD 2026) - "Descriptive characterization of 38 patient courses revealed (¯x±SD): age, 33.47 [9.26] years; 16 [41.1%] female; 2 patients self-identifying as Asian (7.14%), 18 Black/African American (47.37%), 3 White (7.89%), 9 (23.68%) Hispanic/Latino, Other/Unknown (34.21%); BMI, 31.82 [9.80] kg/m. Treatment duration spanned 19.52 [3.72] weeks, with post-therapy follow-up at 7.50 [2.15] weeks. From baseline to endpoint, there were significant declines in HS-PGA (4.00 [1.07] vs 1.97 [1.25], p<0.001) NRS-pain (5.01 [3.09] vs 1.60 [2.19], p<0.001), erythrocyte sedimentation rate (78.89 [38.11] vs 42.58 [33.36] mm/hr, p<0.001), C-reactive protein (43.54 [38.61] vs 22.52 [28.72] mg/dL, p<0.05), and interleukin-6 (28.84 [21.68] vs 12.11 [11.33] pg/mL, p<0.05)."

Clinical • Dermatology • Hidradenitis Suppurativa • Immunology • Inflammation • CRP • IL6

Repeated Intravenous Ertapenem Therapy for Hidradenitis Suppurativa Is Safe and Effective (AAD 2026) - "Descriptive characterization of 38 patients (15 ertapenem-naïve, 23 ertapenem-experienced) were included. Baseline mean age (32.93 vs 33.61 years), BMI (32.09 vs 31.65 kg/m2), HS-PGA (3.93 vs 4.04), and treatment duration (18.50 vs 20.19 weeks) were comparable between groups (all p>0.05). Both ertapenem-naïve and ertapenem-experienced patients demonstrated statistically significant improvement in HS-PGA (p<0.001), NRS-pain (p<0.001), and inflammatory markers (p<0.05) following therapy."

Dermatology • Hidradenitis Suppurativa • Immunology • IL6

Beta-Lactam Intravenous Push Use in a Critical Care Setting: Practice Patterns and Perspectives (SCCM 2026) - "IVP was most frequently reported for cefazolin (46%) and ceftriaxone (41%) and was least commonly used for cefepime (16%), ertapenem (17%), and meropenem (7%). Despite evidence supporting prolonged infusion of various beta-lactams, IVP administration is commonly utilized, with usage varying by agent. While pharmacists are the primary advocates for IVP, many believe it is inappropriate in a critical care setting, though few have conducted formal evaluations. These findings highlight the need to further explore additional considerations for IVP administration of beta-lactams in this setting, such as institutional policies, drug characteristics, and formal evaluations of safety and efficacy."

Critical care • Infectious Disease

Longitudinal Trends in Antimicrobial Susceptibility Among ECMO Patients With Gram-Negative Rods (SCCM 2026) - "We used AI-assisted tools for statistical coding and editorial refinement. Ertapenem maintained >95% susceptibility throughout all years. Meropenem showed a transient drop in 2022 (62.9%) but recovered to 100% by 2023...Ciprofloxacin susceptibility peaked in 2020–2021 before declining in 2023. Due to inconsistent data, piperacillin-tazobactam was excluded from trend analysis. Antimicrobial susceptibility patterns among GNRs in ECMO patients have fluctuated over the past five years. Antimicrobial susceptibility patterns among GNRs in ECMO patients have fluctuated over the past five years. Carbapenems remain reliable, while recovery of susceptibility to narrower-spectrum agents such as ampicillin-sulbactam and cefepime suggests a potential role for empiric antibiotic cycling. ECMO-specific antibiograms provide critical guidance for treatment and support the role of stewardship in curbing MDRO development in this high-risk population."

Clinical • Gram negative • Infectious Disease • Pneumonia

A Multisystem Crisis: Septic Shock With Neuromuscular Weakness and Coagulopathy (SCCM 2026) - "Further coagulopathy labs were negative for disseminated intravascular coagulation (DIC), however he was empirically started on Vitamin K. Antibiotics were tailored for a two week course of ertapenem after blood cultures were positive for ESBL E. coli. Decisions to start IVIG and Vitamin K were important points in this patient's course, and treatment led to significant improvement with some side effects. Our case demonstrates how sepsis induced myopathy can mimic myasthenia gravis, and how ceftaroline and amoxicillin are uncommon antibiotics that can lead to Vitamin K deficiency."

Atrial Fibrillation • Cardiovascular • CNS Disorders • Hematological Disorders • Infectious Disease • Inflammation • Myasthenia Gravis • Myositis • Septic Shock

Why bet when you can pet!! (UKKW 2026) - "Attempts to establish the patient on maintenance immunosuppression were hampered by pancytopenia (azathioprine), recurrent chest infection (aspiration related to cranial nerve palsies), steroid induced psychosis and nutritional compromise (BMI 18 from 31) requiring PEG feeding. Re-induction with rituximab was required after 12 months (nasopharyngeal and chest disease progression), followed by a prompt relapse requiring cyclophosphamide...Avacopan was added pending ENT assessment and CT-PET...A prolonged course of ertapenem was unhelpful and the patient’s clinical condition and GFR deteriorated...Conclusion. This case highlights the challenges differentiating active vasculitis from infective complications of immunosuppression, as well as the value of a second opinion and CT-PET when the clinical course is atypical"

Cardiovascular • CNS Disorders • Glomerulonephritis • Infectious Disease • Lupus Nephritis • Nephrology • Otorhinolaryngology • Rare Diseases • Renal Disease • Septic Shock • Thrombosis • Vasculitis

Between a Heart and a Hard Node: A Difficult Case of Lymphadenopathy (ISHLT 2026) - "For immunosuppression, he was on belatacept, tacrolimus, mycophenolate, and prednisone...He was started on empiric mycobacterial treatment with intravenous amikacin, imipenem, linezolid, ethambutol, and rifabutin...He completed 4 weeks of ertapenem, and has continued on isavuconazole, azithromycin, ethambutol, rifabutin, and tedizolid.Summary This case highlights a challenging presentation of lymphadenopathy with B-symptoms initially concerning for PTLD but was found to have multiple infections. In immunosuppressed patients, overlapping infectious and noninfectious processes can complicate diagnosis. Obtaining comprehensive diagnostic evaluation is essential to identify the cause and initiate appropriate therapy for optimal outcomes."

Clinical • Cardiomyopathy • Cardiovascular • Infectious Disease • Pneumonia

Cumulative cefepime exposure in cancer patients is associated with an increased risk of ertapenem non-susceptible, meropenem susceptible Enterobacterales bacteremia. (PubMed, Microbiol Spectr) - "Univariate analysis revealed any ceftazidime-avibactam (CZA) exposure was associated with developing CSD-E BSI (odds ratio [OR], 7.41; P = 0.01). In addition, we analyzed paired whole-genome sequencing data to assess antimicrobial gene content for mechanistic rationales supporting our clinical findings. The risk factors for CSD-E development identified in this study require further validation in multicenter cohorts."

Journal • Infectious Disease • Oncology

CRISPR-Cas Based Plasmid Design for Multidrug Resistant Klebsiella Pneumoniae Isolates. (PubMed, FEMS Microbiol Lett) - "Minimum inhibitory concentrations (MICs) of imipenem, meropenem, and ertapenem were determined according to EUCAST guidelines...Apramycin (50 μg/mL) was identified as a suitable selection marker. The pSGKP-AmpR(Pro)-ApmR plasmid was successfully constructed, whereas Cas9 and APOBEC constructs could not be cloned. Overall, this study highlights technical challenges in developing CRISPR-based tools for MDR K. pneumoniae and emphasizes the need for isolate-specific plasmid design and gRNA optimization."

Journal • Infectious Disease • Pneumonia

Infection-Associated Thrombotic Microangiopathy in a Simultaneous Pancreas–Kidney Transplant Recipient Successfully Treated with Plasma Exchange While Maintaining Tacrolimus (NKF-SCM 2026) - "Tacrolimus, previously 2 mg twice daily, was reduced to 1 mg twice daily but not discontinued, while mycophenolate and valganciclovir were held. She received ertapenem for bacteremia and G-CSF for neutropenia. Following PLEX, her platelet count normalized (to 156×10⁹/L), LDH declined to 167 U/L, haptoglobin stabilized, neutropenia resolved, and renal function improved, with creatinine reaching 1.58 mg/dL at discharge CONCLUSION This case demonstrates that infection-associated TMA may respond robustly to PLEX without discontinuation of tacrolimus, supporting the safety of maintaining CNI therapy at adjusted doses in carefully selected transplant recipients."

Clinical • Diabetes • Hematological Disorders • Infectious Disease • Metabolic Disorders • Neutropenia • Pneumonia • Thrombocytopenia • Transplantation • Type 1 Diabetes Mellitus • HP

Aerobic pathogen profiles and antibiotic resistance in diabetic foot ulcers: Data from a Specialized Diabetes Center in Jordan. (PubMed, Medicine (Baltimore)) - "The GPB isolates exhibited complete susceptibility to vancomycin, linezolid, tigecycline, and teicoplanin. For Gram-negative bacteria, ertapenem, meropenem, amikacin, and imipenem were the most effective antibiotics...The findings underscore the importance of continued surveillance of bacterial profiles and antibiotic susceptibility patterns in DFUs. Future research is needed to guide the judicious use of antibiotics in empirical therapy for diabetic foot infections."

Journal • Diabetes • Endocrine Disorders • Infectious Disease • Metabolic Disorders

Time to Awaken a Forgotten Antibacterial Agent: A 10-year Nationwide Surveillance of Latamoxef Resistance in China Based on 46,716 Isolates and Establishment of Tentative Epidemiological Cut-Off Values. (PubMed, Infect Drug Resist) - "The in vitro activity of latamoxef against these bacteria, especially extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae, was similar to the activities of ertapenem and meropenem and significantly higher than the activities of ceftriaxone, ceftazidime, and cefepime. Latamoxef has good and stable in vitro antimicrobial activity against Enterobacteriaceae, including ESBL-producing Enterobacteriaceae. The calculated TECOFFs of latamoxef provide an important reference for subsequent use of this antibiotic against Enterobacteriaceae."

Journal • Infectious Disease • Pneumonia

MAPPAC: Acute Appendicitis and Microbiota - Etiology of Appendicitis and Antibiotic Therapy Effects (clinicaltrials.gov) - P=N/A | N=200 | Enrolling by invitation | Sponsor: Turku University Hospital

New trial • Gastroenterology • Gastrointestinal Disorder

MAPPAC: Acute Appendicitis and Microbiota - Etiology of Appendicitis and Antibiotic Therapy Effects (clinicaltrials.gov) - P=N/A | N=200 | Enrolling by invitation | Sponsor: Turku University Hospital | Trial completion date: Apr 2019 ➔ Dec 2025 | Trial primary completion date: Apr 2019 ➔ Dec 2022

Trial completion date • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder